Showing results (141-150 of 151) with videos related to
Sort By:
Pageof 16
The New England Journal of Medicine|September 12, 2017
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV MelanomaJeffrey Weber, Mario Mandala, Michele Del Vecchio, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2023
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238James Larkin, Michele Del Vecchio, Mario Mandalá, et al.Journal for Immunotherapy of Cancer|March 15, 2019
An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE)Derek L Clouthier, Scott C Lien, S Y Cindy Yang, et al.Journal of Proteomics|January 15, 2018
MHC class I loaded ligands from breast cancer cell lines: A potential HLA-I-typed antigen collectionDmitri V Rozanov, Nikita D Rozanov, Kami E Chiotti, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2022
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)Jeffrey S Weber, Dirk Schadendorf, Michele Del Vecchio, et al.Journal for Immunotherapy of Cancer|March 27, 2026
CD8 PET imaging with [89Zr]Zr-berdoxam-crefmirlimab in patients with solid tumors: the Phase II iCorrelate studyMichael A Postow, Peter D Zang, Sumanta K Pal, et al.Journal for Immunotherapy of Cancer|October 2, 2021
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrenceCraig L Slingluff, Karl D Lewis, Robert Andtbacka, et al.Nature Medicine|January 9, 2023
Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trialDavid S Hong, Brian A Van Tine, Swethajit Biswas, et al.Arthritis & Rheumatology (Hoboken, N.J.)|December 29, 2016
Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody-Associated VasculitisPeter A Merkel, Gang Xie, Paul A Monach, et al.Journal for Immunotherapy of Cancer|January 20, 2021
Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibitionAljosja Rogiers, Ines Pires da Silva, Chiara Tentori, et al.Pageof 16